Moderna vaccine started phase to test effectiveness 1:41
(CNN) - Moderna, one of the companies working on a covid-19 vaccine, said Wednesday that it is on track to end registration for a phase three study of its vaccine by the end of September and plans to eventually give it a priced below $ 40 per serving for most clients.
The biotech company, which received funds from the Operation Warp Speed program (which in Spanish means “Operation Maximum Speed”) from the United States federal government, also said it had about $ 400 million in customer deposits for a possible supply of their mRNA-1273 vaccine.
Experts: Advance in vaccines should not relax population 9:53People have also been watching closely to see how much drug companies plan to charge for treatments after biotech Gilead Sciences revealed in June that their remdesivir drug would cost $ 520 per vial, or $ 3,120 for a six-vial cycle. for five days, for people covered by private health insurance plans.
But Moderna CEO Stéphane Bancel promised during a conference call with analysts that his vaccine would be affordable.
“We are working with governments around the world and others to ensure that the vaccine is accessible regardless of ability to pay. And we will be responsible for the price ... during the pandemic, "said Bancel, adding that small amounts of the vaccine so far have cost between $ 32 and $ 37 per dose and that Moderna would charge lower prices for higher volumes. of the mRNA-1273 vaccine.
Moderna made the announcement in its earnings report on Wednesday morning. The company posted a lower-than-expected loss but revenue that exceeded expectations.
Report positive results of vaccine against covid-19 0:37Moderna's shares fell about 2% after the news, but the stock has soared more than 300% this year in hopes that it can develop a successful coronavirus vaccine.
The company has also come under scrutiny by some investors, as insiders have sold shares as the scrutiny increases.
Moderna is just one of several companies competing to invent a vaccine. Shares of another smaller biotech, Novavax, soared 20% on Wednesday after announcing its own promising clinical trial results.
Coronavirus vaccine
